Search

everythinglearnresearchcommunity

for

Search:↓

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

The convention discussed various skin conditions, treatments, and the importance of continuous learning in dermatology nursing.

The study found key factors in the cause of hidradenitis suppurativa, its link to other diseases, and identified existing drugs that could potentially treat it.

Four natural compounds were found to promote hair growth effectively.

Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.

Ginsenoside Rd may help improve skin aging by increasing collagen in the skin.

Aging reduces skin cell renewal and defense against germs due to TGFbeta, but blocking TGFbeta could help restore these functions.

Removing STAT5 from 3D-cultured human skin cells reduces their ability to grow hair.

Kaempferol helps skin stem cells grow and may improve skin thickness due to its 3-OH group.

Type I interferons play a key role in the development of various skin diseases.

The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.

Lactate production is important for activating hair growth stem cells.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

An imbalance between certain immune cells is linked to a chronic skin condition and may be influenced by obesity, smoking, and autoimmune issues.

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

Cholesterol-related compounds can stop hair growth and cause inflammation in a type of scarring hair loss.

Advanced therapies like gene, cell, and tissue engineering show promise for hair regrowth in alopecia, but their safety and effectiveness need more verification.

Using a combination of specific cell cycle regulators is better for safely keeping hair root cells alive indefinitely compared to cancer-related methods.

Faulty inflammasome activation may lead to autoimmune skin diseases and could be a target for new treatments.

A new botanical treatment improved hair growth and symptoms in lichen planopilaris patients.

A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.